ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2008
Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Clinical biomarkers for Lewy body diseases.Cell & bioscience · 2023Review
- Protein kinetics of superoxide dismutase-1 in familial and sporadic amyotrophic lateral sclerosis.Annals of clinical and translational neurology · 2023Article
- Change in Cerebrospinal Fluid Tau Microtubule Binding Region Detects Symptom Onset, Cognitive Decline, Tangles, and Atrophy in Dominantly Inherited Alzheimer's Disease.Annals of neurology · 2023Article
- Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.Alzheimer's & dementia (Amsterdam, Netherlands) · 2022Article
- Biomarkers for neurodegenerative diseases.Nature medicine · 2021Review
- Review
- Revolutionizing Alzheimer's disease and clinical trials through biomarkers.Alzheimer's & dementia (Amsterdam, Netherlands) · 2015Review
- Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics.Frontiers in neurology · 2015Review
- Fitting the epidemiology and neuropathology of the early stages of Alzheimer's disease to prevent dementia.Alzheimer's research & therapy · 2015Article
- Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial.Revue neurologique · 2013Review
- Monitoring autophagy in the treatment of protein aggregate diseases: steps toward identifying autophagic biomarkers.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2013Review
- Dominantly Inherited Alzheimer Network: facilitating research and clinical trials.Alzheimer's research & therapy · 2013Review
- Impact of early intervention and disease modification in patients with predementia Alzheimer's disease: a Markov model simulation.ClinicoEconomics and outcomes research : CEOR · 2011Article
- Natural products as a source of Alzheimer's drug leads.Natural product reports · 2011Review
- Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Alzheimer's disease (AD) is the most common cause of dementia and is an increasing public health problem. Because of the severity and increasing prevalence of the disease in the population, it is urgent that better treatments be developed. Active research efforts over the past several decades have produced a vast knowledge base regarding AD natural history, pathology, and key biological mediators involved in pathogenesis. As knowledge of the biomolecular mechanisms of AD has increased over the past several decades, there has been a growing consensus on the pathophysiology of the disease. These scientific advancements have led to proposals for disease-modifying therapeutic interventions that promise to significantly alter the course of AD. The translation from preclinical models to human studies requires therapeutic biomarkers to increase the likelihood of success. This review covers the current methods and technologies used in the therapeutic translation of proposed disease-modifying therapies for AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.